We found that both GB265 and GB266T, but not the anti-PDL1/anti-TIGIT combination, elicited significant tumor growth suppression (Fig. 6b and Table S3), with no significant effects on body weight (Fig. 6c and Table S4). Here, TIGIT is linked to neoplasm.